Shujing Zhang

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of medical economics

Clinical cancer research : an official journal of the American Association for Cancer Research

PharmacoEconomics

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Zev A Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y Janjigian, Josep Tabernero
Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: A meta-analysis in the neoadjuvant ±adjuvant setting. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Andrea Favre-Bulle, Goran Bencina, Shujing Zhang, Ruixuan Jiang, Daniel Andritschke, Arjun Bhadhuri
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland. Journal of medical economics (2023)
Andrea Favre-Bulle, Goran Bencina, Shujing Zhang, Ruixuan Jiang, Daniel Andritschke, Arjun Bhadhuri
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland. Journal of medical economics (2023)
Andrea Favre-Bulle, Goran Bencina, Shujing Zhang, Ruixuan Jiang, Daniel Andritschke, Arjun Bhadhuri
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland. Journal of medical economics 26 (1) (2023)
Shujing Zhang, Arielle G Bensimon, Ruifeng Xu, Ruixuan Jiang, Alexandra Greatsinger, Adina Zhang, Mizuho Fukunaga-Kalabis, Clemens Krepler
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States. Advances in therapy (2023)
Tingting Qu, Shujing Zhang, Yichen Zhong, Yang Meng, He Guo, Seongjung Joo, Peter C Enzinger
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. PharmacoEconomics 40 (12) (2022)